BridgeMD
A study to learn how safe zilucoplan is in children with generalized myasthenia gravis who participated in a previous study about zilucoplan
EU CTIS ID: 2022-502073-42-00
What this study is testing
Assess the long-term safety and tolerability of an additional 52 weeks (±7 days) of treatment with zilucoplan (ZLP) administered by subcutaneous (sc) injection once daily in pediatric study participants
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participant has completed MG0014 according to the protocol, and further treatment with zilucoplan is in the interest of the participant in the Investigator's opinion
- Participant agrees to receive booster vaccinations against meningococcal infections during the study, if clinically indicated according to the local standard of care
You likely can't join if
- Study participant met any mandatory withdrawal or mandatory permanent IMP discontinuation criteria in MG0014 or permanently discontinued investigational medicinal product (IMP)
- Participant has known positive serology for muscle-specific kinase.
- Participant has a known hypersensitivity to any components of the IMP.
- Participant has a prior history of meningococcal disease
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Korea, Republic of
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Korea, Republic of; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.